Minimized Streptokinase

最小化链激酶

• 批准号: 6485056
• 负责人: WILLIAM JOSEPH COLEMAN
• 金额: $ 14.84万
• 依托单位: KAIROS SCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-15 至 2003-05-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485056
• 关键词: bacterial proteins; biotherapeutic agent; chemical stability; directed evolution; drug design /synthesis /production; fibrin; fibrinolysis; high throughput technology; plasmin; protein engineering; streptokinase

DESCRIPTION (provided by applicant): We propose to create a minimized and modified streptokinase having improved properties relative to the known plasminogen activators currently used in thrombolytic therapy. New methods developed by KAIROS for protein minimization and high-throughput screening of enzyme variants wili be used to find smaller versions of the native protein that have maximal activity on fibrin-containing clots. The minimized streptokinase (mSK) will be designed to have: (1 ) increased specificity for fibrin; (2) increased resistance to degradation by plasmin and other proteases; (3) resistance to inhibitors; (4) thermal stability; and (5) low production cost. In addition, a minimized bacterial protein offers the potential benefit of reduced antigenicity. If successful, a minimized and optimized streptokinase will provide a new alternative biopharmaceutical for the thrombolytic therapy market, which is estimated to be worth over $200 million per year in sales. Successful modification of streptokinase will also provide a model for engineering other therapeutic proteins.

描述（由申请人提供）：我们建议创建一个最小化的和